Our mission
Help more families have healthy babies
We expertise in the research and application of genetic technology in reproductive health. In particular, we aim to help patients struggling with infertility and those afflicted with inheritance disorders.
A global leading genetic technology company
Basecare (stock code: 2170HK) is a leading provider of IVF clinical solutions in China, as well as a company listed in the main board of Hong Kong Stock Exchange. Our mission is to help more families have healthy babies through the development and clinical application of high-throughput sequencing technology. Our vision is becoming a global leading genetic technology company.
Basecare remains a tight adherence to the idea of "making compliant products" and upholds the industrialization road of R&D, registration and sales. Basecare has extended its reach beyond the preimplantation stage to the prenatal and postnatal stages, completing a test kit pipeline that covers the full reproductive cycle. The PGT-A detection kit is the only NMPA approved test kit for IVF. PGD (PGT-M and PGT-SR) detection kits are expected to obtain NMPA registration certificate in 2022 and 2024, respectively.
Basecare provides integrated innovation platform solutions from detection reagents to embryo storage instruments. We aim to realize the fully automated and digitalized intelligent hardware upgrades in the field of assisted reproduction by building high-end equipment R&D and manufacturing center. The clinical high-throughput gene sequencers (DA500) and the ultra-low temperature storage device (BSG800A) will obtain the registration approval in 2022 and 2023, respectively.
Our Values
BaseCare adhere to the concept of "Basecare speed - for everything we do, count every second; Basecare standard - for
everything we do,
strive for perfection;
Basecare spirit - for everything we do, concentrate all efforts" to do everything well.
Base represents the smallest unit of human genetic information;
Care represents care for human health.
We march forward together
From the company's start-up to the clinical application, and then to the approval of PGT-A kit in the
market, the development path in the past 11 years is full of hardships, but more full of passion
and hope. We thank you for all the support you generously gave us in the past decade.
Basecare successfully listed on the HKEX in Feburary 2021, become the first listed company in the field of reproductive health of China.
2021
February
BasePGT-A kit was officially approved by NMPA, becoming the first PGT-A product to obtain class III medical device registration certificate, marks the beginning of a new era of certificated ART genetic testing
2020
March
Completed the world’s largest PGT-A clinical trial with the largest amount of data
2019
November
Obtained the GMP workshop production qualification, has the large-scale medical equipment production capacity, lays the solid foundation for the industrialization.
2018
August
Participated in the development of PGT-A quality control evaluation guidelines, to fill the gap of China's third generation IVF quality control technical standards.
2017
October
Established productive & genetic clinical research center with Thermo fisher.
2016
September
Approval of national innovative medical devices, which raised the level of standardization of third generation IVF industry.
2015
April
Cooperated with Dana gene to complete the registration of second generation sequencer and NIP kit.
2014
May
Set up joint laboratory with Life science to develop the first NIPT detection kit based on second generation sequencer.
2013
June
The company was founded to build a big data biological information analysis platform, and began to provide scientific research services based on the next generation sequencing technology.
